Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BIIB092 in Participants With Progressive Supranuclear Palsy

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BIIB092 in Participants With Progressive Supranuclear Palsy

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Oct 2018

At a glance

  • Drugs Gosuranemab (Primary)
  • Indications Progressive supranuclear palsy
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PASSPORT
  • Sponsors Biogen; Bristol-Myers Squibb
  • Most Recent Events

    • 09 Oct 2018 Trial design presented at the 22nd International Congress of Parkinson's Disease and Movement Disorders
    • 03 Oct 2018 According to a Biogen media release, data from this study will be presented at the upcoming International Congress of Parkinsons Disease and Movement Disorders (MDS)
    • 21 Aug 2018 Higher planned patient number 459 kept as per EudraCT record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top